Back to results
US 11,110,163 B2Granted
Heat stable vaccines
AssigneeInventprise, LLC
InventorsSubhash V. Kapre, Ivan A. Olave
Life of this patent
Estimating the term…
Abstract
The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle suspension with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30° C. and 40° C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30° C., and six months at 50° C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.
Claims36
An immunogenic composition comprising:
- an attenuated strain of a rotavirus at a titer of about 105.9 FFU/mL or higher;
- arginine and sucrose at a ratio of from about 1:1.1-2.5;
- less than or equal to about 1.2% moisture;
- an approximate uniform particle size of about 5 μm or less;
- a buffering agent;
- and
- medium-chain triglyceride (MCT).
4 more elements
An immunogenic composition comprising:
- an attenuated strain of a rotavirus at a titer of about 105.9 FFU/mL or higher;
- less than or equal to about 1.2% moisture;
- an approximate uniform particle size of about 5 μm or less;
- a buffering agent;
- and
- medium-chain triglyceride (MCT), wherein
- the composition has a glass transition temperature of about 60° C. or higher.
4 more elements
Dependencies are inferred from the claim text.